AbbVie, Emblaveo
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options. The drug, which combines aztreonam and avibactam, was approved in combination with metronidazole.
The stock's fall snapped a two-day winning streak.
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
Zacks.com on MSN2d
AbbVie Rises 8% Since Q4 Earnings: Buy, Hold or Sell the Stock?AbbVie ABBV announced strong fourth-quarter 2024 results last week, beating estimates for both earnings and sales. While earnings of $2.16 per share declined around 22% year over year, sales rose 6.1% ...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...
The Motley Fool on MSN7d
Why AbbVie Stock Is Jumping TodayAbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported ...
The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...
AbbVie launched a revamped version of its Allē loyalty program, which ultimately was not adopted by providers. The marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback